Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedemain Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
June 14, 2025 10:48 ET | Source: Celldex Therapeutics, Inc. 77% of…
June 14, 2025 10:48 ET | Source: Celldex Therapeutics, Inc. 77% of…
Sign in to your account